144 related articles for article (PubMed ID: 6118429)
1. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites.
Nishikawa M; Kanamori M; Hidaka H
J Pharmacol Exp Ther; 1982 Jan; 220(1):183-90. PubMed ID: 6118429
[No Abstract] [Full Text] [Related]
2. Cyclic nucleotide phosphodiesterase activity and the platelet release reaction.
Taylor PM; Heptinstall S
Thromb Haemost; 1978 Apr; 39(2):550-1. PubMed ID: 27878
[No Abstract] [Full Text] [Related]
3. Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.
Matsuoka I; Suzuki T
J Cyclic Nucleotide Protein Phosphor Res; 1983; 9(4-5):341-53. PubMed ID: 6147364
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
[No Abstract] [Full Text] [Related]
5. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
Block HU; Förster W; Heinroth I
Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic effects of molsidomine.
Rakovec P
J Cardiovasc Pharmacol; 1980; 2(6):893-4. PubMed ID: 6160337
[No Abstract] [Full Text] [Related]
7. [The effect of molsidomine on left ventricular function in coronary heart disease (author's transl)].
Meyer J; Sprauer R; Krebs W; Erbel R; Schweizer P; Effert S
Dtsch Med Wochenschr; 1980 Aug; 105(35):1210-6. PubMed ID: 6893579
[No Abstract] [Full Text] [Related]
8. Cyclic GMP binding and phosphodiesterase: implication for platelet function.
Hamet P; Coquil JF; Bousseau-Lafortune S; Franks DJ; Tremblay J
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():119-36. PubMed ID: 6202123
[No Abstract] [Full Text] [Related]
9. [Comparison of the effects of SIN-1, sodium nitroprusside and nitrate derivatives on the inhibition of blood platelet aggregation and activation of soluble platelet guanylate-cyclase].
Karrenbrock B; Grewe R; Loeschke K; Gerzer R
Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):251-4. PubMed ID: 2882462
[TBL] [Abstract][Full Text] [Related]
10. The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation.
Basista M; Grodzińska L; Swies J
Thromb Haemost; 1985 Dec; 54(4):746-9. PubMed ID: 3911480
[TBL] [Abstract][Full Text] [Related]
11. Effects of molsidomine and other NO-containing vasodilators on cyclic GMP formation.
Böhme E; Grossman G; Spies C
Eur Heart J; 1983 May; 4 Suppl C():19-24. PubMed ID: 6311553
[No Abstract] [Full Text] [Related]
12. [Molsidomine, a coronary drug with platelet-aggregating inhibitory activity].
Silberbauer K; Slany J; Sinzinger H; Punzengruber C
Z Kardiol; 1982 Aug; 71(8):539-43. PubMed ID: 6753382
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation.
Mellion BT; Ignarro LJ; Myers CB; Ohlstein EH; Ballot BA; Hyman AL; Kadowitz PJ
Mol Pharmacol; 1983 May; 23(3):653-64. PubMed ID: 6135148
[TBL] [Abstract][Full Text] [Related]
14. Mepacrine-induced inhibition of human platelet cyclic-GMP phosphodiesterase.
Yamakado T; Tanaka F; Hidaka H
Biochim Biophys Acta; 1984 Sep; 801(1):111-6. PubMed ID: 6147162
[TBL] [Abstract][Full Text] [Related]
15. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
Hagiwara M; Endo T; Kanayama T; Hidaka H
J Pharmacol Exp Ther; 1984 Feb; 228(2):467-71. PubMed ID: 6141286
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of human platelet guanylate cyclase by nitroso compounds.
Yamakado T; Nishikawa M; Hidaka H
Thromb Res; 1982 Apr; 26(2):135-40. PubMed ID: 6126017
[No Abstract] [Full Text] [Related]
17. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase--basic and potential clinical applications.
Hidaka H; Endo T
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():245-59. PubMed ID: 6144253
[No Abstract] [Full Text] [Related]
18. [Effect of Molsidomin on the hemodynamics and working tolerance of patients with angina pectoris].
Slany J; Mösslacher H; Schmoliner R; Krinik G
Med Welt; 1976 Dec; 27(49):2396-2400. PubMed ID: 796622
[No Abstract] [Full Text] [Related]
19. Influence of aspirin, molsidomine, trapidil, and some trapidil derivatives on arachidonic acid induced reversible thrombocyte aggregation in the rabbit.
Zehl U; Mest HJ; Förster W
Biomed Biochim Acta; 1984; 43(8-9):S381-4. PubMed ID: 6440554
[TBL] [Abstract][Full Text] [Related]
20. Phorbol myristate acetate stimulation of lymphocyte guanylate cyclase and cyclic guanosine 3':5'-monophosphate phosphodiesterase and reduction of adenylate cyclase.
Coffey RG; Hadden JW
Cancer Res; 1983 Jan; 43(1):150-8. PubMed ID: 6128071
[No Abstract] [Full Text] [Related]
[Next] [New Search]
